MTOR and nonpapillary renal cell carcinoma: In prior studies, nivolumab exhibited enhanced OS when compared to everolimus, an mTOR inhibitor, in patients with previously treated ccRCC (Cancer Genome Atlas Research Network, 2013; Miao et al., 2018; Braun et al., 2020).